-
Signature
-
/s/ Avraham S. Adler, Attorney-in-Fact
-
Issuer symbol
-
PTCT
-
Transactions as of
-
30 Dec 2025
-
Net transactions value
-
-$619,941
-
Form type
-
4
-
Filing time
-
02 Jan 2026, 17:20:05 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Klein Matthew B. |
CHIEF EXECUTIVE OFFICER, Director |
C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN |
/s/ Avraham S. Adler, Attorney-in-Fact |
02 Jan 2026 |
0001808968 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
PTCT |
Common Stock |
Sale |
$619,941 |
-8,089 |
-2.3% |
$76.64 |
341,875 |
30 Dec 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: